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Objective: Early anti-platelet therapy is a cornerstone in the prevention of recurrent
ischaemic stroke (IS) and transient ischaemic attacks (TIAs), although the responsiveness
to anti-platelet medications varies among patients. Several studies have reported that
patients with ischaemic stroke who exhibit high on-treatment platelet reactivity (HTPR)
5–10 days after antiplatelet medication onset, have an increased risk of vascular events.
In this study we aim to determine the prevalence of HTPR in the hyper-acute stroke phase
less than 48 h from symptom onset, after the administration of a 300mg bolus of oral
clopidogrel in a real-world setting in Danish IS and TIA patients.
Material and Methods: In total, 219 Danish patients with acute IS or TIA received
300mg of oral clopidogrel on admission. Blood samples from all patients were analyzed
using the VerifyNow P2Y12 system at 8–24 h after clopidogrel intake. Concomitant
therapy and the intervals between ictus and blood collection, clopidogrel intake and blood
collection, and blood sampling and analysis were recorded for all patients.
Results: HTPR in the hyper-acute stroke phase was observed in 28.8% (63/219)
samples. After adjustment for age, sex, co-morbidities, and co-medications, none of the
tested variables exhibited an association with HTPR or the platelet reaction unit value
measured using the VerifyNow P2Y12 system.
Conclusions: The recognition of HTPR to specific anti-platelet agents in the hyper-acute
phase after stroke may be the first step toward interventions that may further minimize
the early recurrent stroke risk. Further large randomized trials including clinical outcome
assessments are necessary.
Keywords: anti-platelet therapy, cerebrovascular disease, clopidogrel, high on-treatment platelet reactivity,
prevention, recurrent stroke, stroke
INTRODUCTION
Anti-platelet therapy is a cornerstone in the prevention of secondary ischaemic stroke (IS), and
clopidogrel has been reported to lower the long-term risk of recurrent stroke with the same
efficiency as acetylsalicylic acid combinedwith dipyridamole (1). Patients with a transient ischaemic
attack (TIA) exhibit an increased stroke risk in the acute phase (2) although this risk is lowered
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after treatment with anti-platelet agents (3). The importance
of very early treatment in both acute IS and TIA has been
further established in a recent time-course analysis of existing
randomized trials (4). However, the platelet function was not
explored in these studies. Although the prevalence of patients
with IS who exhibit high on treatment platelet reactivity (HTPR),
also known as non-responders, has been evaluated in several
other studies, the results have been highly variable (8–61%) (5).
Clopidogrel is an anti-platelet aggregation drug that inhibits
adenosine 5-diphosphate from binding to its P2Y12 receptor on
the surface of the platelet, resulting in the inhibition of platelet
reactivity. This pro-drug requires biotransformation (two-step
oxidation) that is catalyzed by several cytochrome P450 (CYP)
enzymes. A previous study recommended that platelet reactivity
should be tested at 8 h after the administration of a loading dose
of 300mg (6).
In a recent meta-analysis, it was found that the recurrent
stroke or TIA risk was significantly higher in patients with HTPR
(RR = 1.81), and that the HTPR prevalence after clopidogrel
administration was 27% (7). However, the studies included in this
meta-analysis differed with regard to the ethnicity of patients,
treatment regimen, HTPR assessment technique, and treatment
period at the time of HTPR testing. And importantly, the studies
evaluated HTPR >3 days after treatment start.
The aim of the present study was to establish the prevalence of
HTPR at 8–24 h after the intake of clopidogrel 300mg in the acute
phase (<48 h after symptom onset) after IS or TIA in a real-world
setting.
MATERIALS AND METHODS
This prospective cross-sectional study included patients with
suspected acute IS or TIA who were admitted in our stroke
unit, which is a primary treatment center receiving patients
not previously seen by a physician. The study was approved
by the local ethics committee of Region Zealand, Denmark
(protocol number: SJ-390) and registered in clinicaltrials.gov
(NCT02607358).
Patient Selection
Inclusion criteria
• Clinically suspected acute IS or TIA (acute onset of focal
neurological symptoms originating from one vascular area of
the brain and no other explanation of symptoms on brain CT)
within the last 48 h
• Treatment with clopidogrel 300mg on admission
• Provision of verbal and written informed consent prior to
inclusion.
Exclusion criteria
• Previous clopidogrel treatment
• Hemorrhage or pathologies other than IS on brain CT
• Cancer
• Increased bleeding risk (e.g., recent major surgery) or ongoing
bleeding (e.g., low hemoglobin, gastric ulcer)
• Treatment with vitamin K antagonists, novel oral anti-
coagulants, and other adenosine diphosphate (ADP) inhibitors
or non-steroidal anti-inflammatory drugs (NSAIDs) other
than acetylsalicylic acid (ASA)
• Unmet criteria for a diagnosis of ischaemic stroke or TIA at
discharge
• Abnormal haematocrit (Hct) values (range, 30–52%) or
platelet counts (range, 119–502 × 103/µL) as per VerifyNow
P2Y12 system (Accumetrics, San Diego, California)instruction
manual
Clinical Procedures
Routine blood tests were performed at the time of admission.
Data pertaining to cardiovascular risk factors and demographic
characteristics, including age, sex, ethnicity, the presence
of ischaemic heart disease (IHD), the presence of diabetes
mellitus, and the smoking status (cigarettes or pipe in any
amount until 1 week before admission), were recorded for
all patients. Information concerning treatment with anti-
hypertensive medications and statins as well as concomitant
medical therapy at the time of admission with anti-depressives
TABLE 1 | Baseline characteristics of patients with acute ischaemic stroke or a
transient ischaemic attack.
All patients
(n = 219)
Non-HTPR
group
(n = 156)
HTPR group
(n = 63)
Age, years (SD) 68.7 ± 12.5 67.1 ± 12.8 72.8 ± 10.9
Female sex (%) 90 (41.1) 61 (39.1) 29 (46.0)
IHD (%) 23 (10.6) 14 (9.2) 9 (14.3)
Previous stroke (%) 25 (11.5) 15 (9.7) 10 (15.9)
Diabetes mellitus (%) 22 (10.0) 11 (7.1) 11 (17.5)
Smoking (%) 55 (25.2) 45 (29.0) 10 (15.9)
Carotid stenosis (%) 9 (4.1) 6 (4.7) 3 (5.5)
Platelet count (SD) 244 ± 62 251 ± 66 227 ± 56
Hgb (SD) 9.0 ± 0.9 9.2 ± 0.8 8.5 ± 0.8
Hct (SD) 38 ± 3.9 39.1 ± 3.8 36.8 ± 3.6
CT-infarction (%) 74 (33.8) 48 (31.0) 26 (41.3)
MRI performed (%) 35 (16.0) – –
MRI-infarction (%) 26 (11.9) 20 (12.8) 6 (9.5)
Holter monitoring performed (%) 137 (63.1) 101 (65.2) 36 (58.1)
Atrial fibrillation (%) 34 (15.6) 23 (22.8) 11 (30.6)
Readmission (%) 23 (10.5) 16 (10.3) 7 (11.1)
Ischaemic stroke vs. TIA (%) 153 (69.9) 112 (71.8) 41 (65.1)
Anti-hypertensive treatment (%) 91 (41.7) 59 (38.1) 32 (50.8)
Statin treatment (%) 35 (16.1) 19 (12.3) 16 (25.4)
PPI treatment (%) 29 (13.2) 15 (9.6) 14 (22.2)
Anti-depressive treatment (%) 10 (4.6) 8 (5.1) 2 (3.2)
HTPR, high on-treatment platelet reactivity; IHD, ischaemic heart disease; Hgb,
hemoglobin; Hct, haematocrit; CT-infarction, sign of early ischaemic lesions on brain-CT;
MRI-infarction, sign of ischaemic lesions in clinical relevant area on MRI; TIA, transient
ischaemic attack; PPI, proton pump inhibitor; CT, computed tomography; MRI, magnetic
resonance imaging; SD, standard deviation; HTPR group, high on-treatment platelet
reactivity after the intake of clopidogrel 300mg in the acute phase of ischaemic stroke
or TIA.
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[selective serotonin re-uptake inhibitors (SSRIs)] and proton
pump inhibitors (PPIs) was also collected (Table 1).
On exclusion of hemorrhage via brain imaging, all patients
received oral clopidogrel 300mg and ASA 300mg under the
supervision of a physician or nurse in order to ensure medication
adherence.
An additional work-up for stroke was conducted according
to local guidelines. This included carotid Doppler ultrasound;
electrocardiography (ECG); 24 h heart rhythm monitoring
during admission, with additional 7 day Holter monitoring
in selected patients; and tests for hypercoagulable states
(e.g., factor V Leiden, elevated homocysteine, fibrinolytic, and
dysfibrinogenic disorders) conducted for selected patients at the
discretion of the treating physician.
Blood Sampling
As per instructions of the manufacturer of VerifyNow, blood
samples for the assessment of HTPR were collected in buffered
sodium citrate tubes provided by the manufacturer at 8–24 h
after clopidogrel Intake, primarily in the morning after an
overnight fast and a rest period of at least 20–30min. Careful
antecubital venipuncture was performed by an experienced nurse
or physician using a Vacutainer Safety-Lok system (Becton
Dickinson, Franklin Lakes, New Jersey, USA) with a pre-attached
holder and a 21-gauge syringe.
Platelet Function Test
The VerifyNow P2Y12 system is a rapid platelet-function
cartridge-based assay designed for direct measurement of the
effects of drugs on the P2Y12 receptor. Platelet aggregation
samples were analyzed 10–240min after collection using the
VerifyNow P2Y12 Assay according to the manufacturer’s
instructions. The results were expressed as platelet reaction
units (PRU).Patients with HTPR were defined as drug-compliant
patients with an ex vivo PRU value of >208 (8).
The VerifyNow system can evaluate clopidogrel effect in
patients receiving dual antiplatelet therapy with ASA (9).
Statistical Analysis
All statistical analyses were performed using IBM SPSS software
for Windows release 24 (Chicago, Illinois, USA), with assistance
FIGURE 1 | Study flow chart. The stroke unit is a primary treatment center receiving patients not previous seen by a physician. AIS, acute ischaemic stroke; TIA,
transient ischaemic attack; ICA, internal carotid artery.
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from the local statistical department at Zealand University
Hospital. All data, except the intervals between ictus and blood
sample collection and blood sample collection and analysis,
were normally distributed. Differences in continuous variables
between groups were analyzed using Student’s t-test with Levine’s
test for equality of variances or the Mann–Whitney U test, as
appropriate. For dichotomous data, the chi-square test was used,
with the use of Fisher’s exact test when the expected values in 2×
2 tables were below 5.
Univariate and multivariate linear regression analyses were
performed to determine independent predictors of the PRU
value and HTPR. A p-value of <0.05 was considered statistically
significant.
RESULTS
Of 366 patients with suspected acute IS or TIA, 219 were eligible
(Figure 1).
Factors Associated With HTPR
In total, 28.8% (63 patients) exhibited HTPR (Table 1). Table 2
depicts the findings of the univariate and multivariate logistic
regression analysis to determine risk factors for HTPR.
The univariate analysis revealed that increasing age, diabetes
mellitus, PPI-treatment, and statin treatment were positively
associated with HTPR whereas smoking, higher platelet count
and higher Hct-value were negatively associated with HTPR.
In the multivariate analysis, factors from the univariate
analysis with a p-value <0.1 were included and adjusted for sex.
In the multivariate analysis, only platelet count and Hct had a
significant effect on HTPR (Table 2).
Factors Associated With the PRU Value
In Table 3 is listed the different variables tested for effects on the
PRU. PRU values were lower in smokers and patients without
diabetes. The remaining tested binary variables did not show
significant effect on the PRU.
The intervals between ictus and blood collection (p = 0.52),
clopidogrel bolus administration and blood collection (p= 0.28),
and blood collection and analysis (p = 0.79) did not affect the
PRU value (Figure 2).
However, the PRU value was negatively correlated with the
platelet count, Hgb level, and Hct value (Figure 3).
In multiple regression analysis, none of the variables except
the platelet count (p = 0.006) and Hct value (p = 0.006) was
significant after adjustment for age, sex, the smoking status, anti-
hypertensive treatment, PPI treatment, previous stroke history,
the presence of IHD, statin treatment, and the presence of
diabetes mellitus.
DISCUSSION
In the present study, 28.8% patients with acute IS or TIA
exhibited HTPR after the supervised intake of clopidogrel 300mg
(ensured compliance) in the acute phase after stroke.
According to multivariate analysis, only the Hct value and
platelet count influenced HTPR and the PRU value; a decreased
Hct value and platelet count resulted in a high PRU value. The
VerifyNow system is sensitive to the Hct value (10) and platelet
count; therefore, the above finding was probably an indicator of
technical issues with the point-of-care device rather than a sign
of clopidogrel-induced HTPR.
Our findings are in line with those of a recent meta-analysis,
(7) which found that the prevalence of HTPR in clopidogrel-
treated stroke patients was 27%. An impaired response to anti-
platelet treatment may play a role in the risk of early stroke
recurrence and could explain the reason why dual anti-platelet
therapies with different modes of action lower the risk of serious
vascular events when administered in the acute phase after stroke
(11). If previous large randomized controlled trials on the effects
of clopidogrel (1, 12) had adjusted for patients with HTPR, the
TABLE 2 | Findings of univariate and multivariate regression analyses of suspected risk factors for high on-treatment platelet reactivity after the administration of
clopidogrel 300mg in the acute phase of ischaemic stroke or a transient ischaemic attack.
Univariate analysis Multivariate analysis
Risk factor OR (95% CI) p-value OR (95% CI) p-value
Age 1.04 (1.01–1.07) <0.01 1.03 (0.995–1.06) 0.10
Female sex 1.33 (0.74–2.40) 0.35 1.11 (0.54–2.27) 0.78
Diabetes mellitus 2.79 (1.14–6.82) 0.03 1.74 (0.59–5.11) 0.31
PPI treatment 2.50 (1.14–5.50) 0.02 2.10 (0.87–5.08) 0.10
Statin treatment 2.42 (1.15–5.09) 0.02 1.72 (0.69–4.33) 0.25
Anti-hypertensive treatment 1.68 (0.93–3.03) 0.09 1.17 (0.59–2.34) 0.66
IHD 1.66 (0.68–4.05) 0.27 Not tested
Anti-depressive treatment 0.61 (0.13–2.94) 0.54 Not tested
Smoking 0.46 (0.22–0.99) 0.04 0.87 (0.37–2.07) 0.76
Platelet count 0.99 (0.988–0.998) 0.01 0.99 (0.986–0.997) 0.01
Hct 0.84 (0.77–0.92) <0.01 0.87 (0.79–0.96) 0.01
OR, odds ratio; CI, confidence interval; PPI, proton pump inhibitor; IHD, ischaemic heart disease; Hct, haematocrit. Significant p-values (<0.05) are highlighted in bold.
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TABLE 3 | Independent samples t-test (top) or linear regression (bottom) on effects of different variables on the platelet reaction unit value measured using the
whole-blood VerifyNow P2Y12 assay.
PRU mean ± SD Mean difference (95% CI) p-value
Sex
Male 161 ± 71
Female 164 ± 75 −3.48 (−23.2; 16.3) 0.73
Current smoking
Smokers 143 ± 67
Non-smokers 169 ± 74 25.0 (3.8; 48.2) 0.02
Diabetes mellitus
Diabetic 198 ± 65
Not diabetic 158 ± 73 −39.8 (−71.7; −7.9) 0.02
PPI-treatment
Yes 177.1 ± 87
No 159 ± 70 −15.6 (−51.8; 17.1) 0.31
Anti-hypertensive treatment
Yes 165 ± 84
No 160.1 ± 64 −4.4 (−25.1; 16.3) 0.67
Statin treatment
Yes 173 ± 93
No 160 ± 69 −13.4 (−46.7; 20.0) 0.42
Anti-depressive treatment
Yes 137 ± 79
No 163 ± 72 26.6 (−19.8; 73.1) 0.26
IHD
Yes 173 ± 76
No 162 ± 72 −11.1 (−42.7; 20.4) 0.49
Previous stroke
Yes 175 ± 89
No 161 ± 71 −14.3 (−44.9; 16.2) 0.36
Beta (95% CI) p-value
Age 0.12 (−0.09; 1.46) 0.08
Hgb −0.32 (−36.2; −14.4) <0.001
Platelet count −0.19 (−0.38; −0.07) 0.004
Hematocrit −0.23 (−6.8; −1.9) <0.001
Interval between ictus and blood sample collection (h) −0.04 (−1.07; 0.54) 0.52
Interval between clopidogrel administration (300-mg bolus) and blood sample collection (h) −0.07 (−0.06; 0.02) 0.28
Interval between blood sample collection and PRU analysis (min) −0.02 (−0.16; 0.21) 0.79
PPI, proton pump inhibitor; IHD, ischaemic heart disease; Hgb, haemoglobin; SD, standard deviation. Significant p-values (<0.05) are highlighted in bold.
prophylactic efficacy of clopidogrel for patients without HTPR
could have been better than anticipated.
Group Differences
In the present study, patients with HTPR after clopidogrel
intake were older than those without HTPR (72.8 vs. 67.1 years;
p= 0.002). This is consistent with previous findings (13) showing
diminished anti-platelet effects with increasing age. This could be
attributed to the decrease in the activity of several CYP enzymes,
including CYP2C19 and CYP1A2, which are responsible for the
conversion of clopidogrel to its active metabolite via two-step
oxidation, with an increase in age (>65 years) (14).
We also confirmed the previously reported “smokers paradox”
in the present study, where the PRU value was lower for
smokers than for non-smokers. Some CYP enzymes involved
in the oxidation required to convert clopidogrel to its active
form (15) are induced by smoking (16). Despite the “smoking
paradox”, defined as the effect of smoking on clopidogrel
conversion, smoking remains a strong independent risk factor for
cardiovascular death (17).
In the present study, the number of patients with HTPR and a
high PRU value was higher among patients with diabetes mellitus
than among those without. This finding is consistent with the
findings of previous studies (18) and is probably a consequence
of platelet hyper-reactivity due to platelet anomalies in patients
with diabetes (19).
Among the concomitant medications tested in the present
study, statins and PPIs appeared to influence HTPR according to
Frontiers in Neurology | www.frontiersin.org 5 August 2018 | Volume 9 | Article 712
Rath et al. HTPR in Danish Ischemic Stroke Patients
FIGURE 2 | Platelet reaction unit timing results. (A) Association of the platelet reaction unit (PRU) value with the interval between stroke onset (ictus) and blood sample
collection (h). (B) Association of the PRU value with the interval between clopidogrel administration (300-mg bolus) and blood sample collection (h). (C) Association of
the PRU value with the interval between blood sample collection and PRU analysis (min).
FIGURE 3 | Linear regression analysis for the association of platelet reactivity [measured using Platelet Reaction Units (PRU)] with the haematocrit (Hct) value (A) and
platelet count (B). Decreased platelet reactivity is associated with an increased Hct value and platelet count.
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univariate analysis, although their effect became insignificant in
multivariate analysis. Moreover, these medications did not affect
the PRU value. Drugs metabolized by the CYP2C19 pathway,
such as omeprazole, esomeprazole, and citalopram, have been
suspected of masking the effects of clopidogrel because of
CYP2C19 inhibition. Some studies have suggested the use of
other PPIs (20). We only evaluated the effects of different PPIs
as a single group in our study. If each generic PPI is individually
tested, the results could be different. This, however, requires a
much larger study.
A recent meta-analysis by Bykov et al. (21) found that a small
decrease in the effectiveness of clopidogrel was associated with
concomitant exposure to CYP2C19-inhibiting SSRIs. However,
none of the patients in our study received CYP2C19-inhibiting
SSRIs.
The VerifyNow System
The VerifyNow system was chosen as the test device in the
present study, because the results obtainedwith this point-of-care
device have previously been correlated with clinical outcomes
(22) most recently in a systematic review and meta-analysis
of patients with cardiovascular disease (23). Furthermore, this
system can evaluate the clopidogrel response in patients receiving
dual anti-platelet treatment with clopidogrel and ASA (24).
Several studies have indicated poor treatment compliance as
the most important reason for unsatisfactory platelet inhibition
(25). In the present study, compliance was ensured because
the drug intake by all patients was carefully supervised and
documented in the hospital setting.
Accordingly, the poor clopidogrel response could be
attributed to biochemical interactions, pharmacokinetics, or, in
some cases, genetic factors.
Limitations
This study has some limitations. The cross-sectional design leaves
no opportunity for repeated measurements of the PRU value and
provides no information on the clinical outcomes of patients.
Both these factors would be very useful in a clinical setting. In
addition, sub-group analysis was limited because of the small
sample size, and this could have resulted in undetected effects of
different variables.
The PPI-subgroup reflects only patients previous treated
with PPI at not those prescribed PPIs at time of clopidogrel
loading dose. If both premorbid PPI-treated patients and those
prescribed PPI at the time of bolus were tested as a group, we
might have seen a difference.
Unfortunately, we did not have data on patients with
premorbid aspirin use. Even though the VerifyNow is designed
to distinguish platelet inhibition with clopidogrel from that of
aspirin, this subgroup would still have been interesting because
one must assume that these patients have a more premorbid
cardiovascular disease. A more standardized approach for the
timing of blood collection after clopidogrel intake and an optimal
time interval between blood collection and analysis would
minimize any concerns about the effects of these time gaps on
the study results. However, this study was conducted in an actual
clinical setting, and standardization of these time intervals was
not possible. Nevertheless, these time intervals did not influence
HTPR or the PRU value.
Baseline measurement of the PRU value before the
administration of clopidogrel could predict the PRU value
after clopidogrel intake. This, however, was not possible in our
study, because it would have delayed the time to anti-platelet
treatment initiation. Evaluation of other platelet parameters
such as immature platelets and thromboxane would also be
interesting, although such evaluations are not part of the routine
set-up and were consequently omitted in our study. Finally, this
study aimed to evaluate the prevalence of non-responders in the
immediate acute phase after stroke. We acknowledge that the
“long-term” responder status may change; however, this was not
within the scope of our study.
In conclusion, our findings showed that the administration
of clopidogrel 300mg in the acute phase after IS or TIA
resulted in HTPR in approximately one-third of the patients. The
recognition of HTPR to specific anti-platelet agents in the acute
phase after stroke may be the first step toward interventions that
may further minimize the early recurrent stroke risk. Further
large randomized trials including clinical outcome assessments
are necessary.
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